Compare $BIAF vs $LIMN | Chartloom

Compare

$BIAF vs $LIMN

bioAffinity Technologies Inc · Liminatus Pharma Inc

BIAF

bioAffinity Technologies Inc

LIMN

Liminatus Pharma Inc

Compare $BIAF vs $LIMN

Comparing bioAffinity Technologies Inc and Liminatus Pharma Inc

BIAFbioAffinity Technologies Inc

LIMNLiminatus Pharma Inc

BIAFbioAffinity Technologies Inc

Market cap

$37M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-23.2%

YTD performance

-74.2%

52W performance

-89.7%

FCF yield

-31.5%

LIMNLiminatus Pharma Inc

Market cap

$253M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-88.3%

52W performance

-95.3%

FCF yield

-1.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BIAF

LIMN

Detailed metrics comparison

BIAF

bioAffinity Technologies Inc

LIMN

Liminatus Pharma Inc

Market Cap

BIAF$37M

LIMN$253M

Enterprise Value

BIAF$35M

LIMN$251M

Price

BIAF$4.73

LIMN$3.76

P/E Ratio

BIAFN/A

LIMNN/A

P/S Ratio

BIAF6.23x

LIMN0.00x

EV/Sales

BIAF5.93x

LIMN0.00x

EV/EBITDA

BIAF0.00x

LIMN0.00x

P/B Ratio

BIAF1.87x

LIMN17.43x

P/FCF Ratio

BIAFN/A

LIMNN/A

EV/FCF

BIAF-3.02x

LIMN-62.96x

PEG Ratio

BIAFN/A

LIMNN/A

Forward P/E (NTM)

BIAFN/A

LIMNN/A

Forward P/S (NTM)

BIAFN/A

LIMNN/A

Revenue (TTM)

BIAF$6M

LIMN$0

Revenue Growth (YoY)

BIAF-23.2%

LIMNN/A

Forward Rev Growth

BIAF0.0%

LIMN0.0%

Gross Margin (TTM)

BIAF34.6%

LIMN0.0%

Operating Margin (TTM)

BIAF0.0%

LIMN0.0%

EBITDA Margin (TTM)

BIAF-202.8%

LIMN0.0%

Net Margin (TTM)

BIAF-257.3%

LIMN0.0%

FCF Margin (TTM)

BIAF-196.0%

LIMNN/A

Net Income (TTM)

BIAF$-15M

LIMN$-13M

FCF (TTM)

BIAF$-12M

LIMN$-4M

EPS (TTM)

BIAF-$43.57

LIMN-$12.94

ROE (TTM)

BIAF-25727.0%

LIMN0.0%

ROA (TTM)

BIAF-15954.0%

LIMN-62234.0%

ROIC (TTM)

BIAF-23305.0%

LIMN0.0%

Cash

BIAF$2M

LIMN$3M

Debt

BIAF$634K

LIMN$1M

Net Cash/Debt

BIAF$2M

LIMN$2M

Current Ratio (TTM)

BIAF1.44x

LIMN1.12x

Quick Ratio (TTM)

BIAF1.36x

LIMN0.99x

Debt/Equity (TTM)

BIAF0.17x

LIMN4.80x

Debt/Assets (TTM)

BIAF0.0%

LIMN0.0%

Interest Coverage (TTM)

BIAFN/A

LIMNN/A

Net Debt/EBITDA (TTM)

BIAF0.00x

LIMN0.00x

Beta

BIAF-1.26

LIMN0.75

52W Performance

BIAF-89.7%

LIMN-95.3%

YTD Performance

BIAF-74.2%

LIMN-88.3%

% from 52W High

BIAF-94.1%

LIMN-97.3%

% from 52W Low

BIAF3.6%

LIMN14.3%

Asset Turnover (TTM)

BIAF0.62x

LIMN0.00x

FCF Yield (TTM)

BIAF-31.5%

LIMN-1.6%

Earnings Yield (TTM)

BIAF-41.3%

LIMN-5.0%

Dividend Yield (TTM)

BIAFN/A

LIMNN/A

Rule of 40

BIAF-219.2

LIMN0.0

EV/GP/RG

BIAFN/A

LIMNN/A

Ticker research

View BIAF research View LIMN research

Metric	BIAF bioAffinity Technologies Inc	LIMN Liminatus Pharma Inc
Market & Valuation
Market Cap	$37M	$253M
Enterprise Value	$35M	$251M
Price	$4.73	$3.76
P/E Ratio	N/A	N/A
P/S Ratio	6.23x	0.00x
EV/Sales	5.93x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.87x	17.43x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.02x	-62.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$6M	$0
Revenue Growth (YoY)	-23.2%	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	34.6%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-202.8%	0.0%
Net Margin (TTM)	-257.3%	0.0%
FCF Margin (TTM)	-196.0%	N/A
Net Income (TTM)	$-15M	$-13M
FCF (TTM)	$-12M	$-4M
EPS (TTM)	-$43.57	-$12.94
ROE (TTM)	-25727.0%	0.0%
ROA (TTM)	-15954.0%	-62234.0%
ROIC (TTM)	-23305.0%	0.0%
Financial Health
Cash	$2M	$3M
Debt	$634K	$1M
Net Cash/Debt	$2M	$2M
Current Ratio (TTM)	1.44x	1.12x
Quick Ratio (TTM)	1.36x	0.99x
Debt/Equity (TTM)	0.17x	4.80x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.26	0.75
52W Performance	-89.7%	-95.3%
YTD Performance	-74.2%	-88.3%
% from 52W High	-94.1%	-97.3%
% from 52W Low	3.6%	14.3%
Efficiency & Yields
Asset Turnover (TTM)	0.62x	0.00x
FCF Yield (TTM)	-31.5%	-1.6%
Earnings Yield (TTM)	-41.3%	-5.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-219.2	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BIAF research	View LIMN research

Valuation

P/S Ratio

LIMN

0.00x

BIAF

6.23x

EV/FCF

LIMN

-62.96x

BIAF

-3.02x

Growth & revenue

Revenue Growth TTM

BIAF

-23.2%

Forward Revenue Growth

BIAF

0.0%

LIMN

0.0%

Profitability & performance

Gross Margin

BIAF

34.6%

LIMN

0.0%

ROE

LIMN

0.0%

BIAF

-25727.0%

FCF Yield %

LIMN

-1.6%

BIAF

-31.5%

52-Week Performance

BIAF

-89.7%

LIMN

-95.3%

Detailed metrics comparison

BIAF

bioAffinity Technologies Inc

LIMN

Liminatus Pharma Inc

Market Cap

BIAF$37M

LIMN$253M

Enterprise Value

BIAF$35M

LIMN$251M

Price

BIAF$4.73

LIMN$3.76

P/E Ratio

BIAFN/A

LIMNN/A

P/S Ratio

BIAF6.23x

LIMN0.00x

EV/Sales

BIAF5.93x

LIMN0.00x

EV/EBITDA

BIAF0.00x

LIMN0.00x

P/B Ratio

BIAF1.87x

LIMN17.43x

P/FCF Ratio

BIAFN/A

LIMNN/A

EV/FCF

BIAF-3.02x

LIMN-62.96x

PEG Ratio

BIAFN/A

LIMNN/A

Forward P/E (NTM)

BIAFN/A

LIMNN/A

Forward P/S (NTM)

BIAFN/A

LIMNN/A

Revenue (TTM)

BIAF$6M

LIMN$0

Revenue Growth (YoY)

BIAF-23.2%

LIMNN/A

Forward Rev Growth

BIAF0.0%

LIMN0.0%

Gross Margin (TTM)

BIAF34.6%

LIMN0.0%

Operating Margin (TTM)

BIAF0.0%

LIMN0.0%

EBITDA Margin (TTM)

BIAF-202.8%

LIMN0.0%

Net Margin (TTM)

BIAF-257.3%

LIMN0.0%

FCF Margin (TTM)

BIAF-196.0%

LIMNN/A

Net Income (TTM)

BIAF$-15M

LIMN$-13M

FCF (TTM)

BIAF$-12M

LIMN$-4M

EPS (TTM)

BIAF-$43.57

LIMN-$12.94

ROE (TTM)

BIAF-25727.0%

LIMN0.0%

ROA (TTM)

BIAF-15954.0%

LIMN-62234.0%

ROIC (TTM)

BIAF-23305.0%

LIMN0.0%

Cash

BIAF$2M

LIMN$3M

Debt

BIAF$634K

LIMN$1M

Net Cash/Debt

BIAF$2M

LIMN$2M

Current Ratio (TTM)

BIAF1.44x

LIMN1.12x

Quick Ratio (TTM)

BIAF1.36x

LIMN0.99x

Debt/Equity (TTM)

BIAF0.17x

LIMN4.80x

Debt/Assets (TTM)

BIAF0.0%

LIMN0.0%

Interest Coverage (TTM)

BIAFN/A

LIMNN/A

Net Debt/EBITDA (TTM)

BIAF0.00x

LIMN0.00x

Beta

BIAF-1.26

LIMN0.75

52W Performance

BIAF-89.7%

LIMN-95.3%

YTD Performance

BIAF-74.2%

LIMN-88.3%

% from 52W High

BIAF-94.1%

LIMN-97.3%

% from 52W Low

BIAF3.6%

LIMN14.3%

Asset Turnover (TTM)

BIAF0.62x

LIMN0.00x

FCF Yield (TTM)

BIAF-31.5%

LIMN-1.6%

Earnings Yield (TTM)

BIAF-41.3%

LIMN-5.0%

Dividend Yield (TTM)

BIAFN/A

LIMNN/A

Rule of 40

BIAF-219.2

LIMN0.0

EV/GP/RG

BIAFN/A

LIMNN/A

Ticker research

View BIAF research View LIMN research

Metric	BIAF bioAffinity Technologies Inc	LIMN Liminatus Pharma Inc
Market & Valuation
Market Cap	$37M	$253M
Enterprise Value	$35M	$251M
Price	$4.73	$3.76
P/E Ratio	N/A	N/A
P/S Ratio	6.23x	0.00x
EV/Sales	5.93x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.87x	17.43x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.02x	-62.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$6M	$0
Revenue Growth (YoY)	-23.2%	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	34.6%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-202.8%	0.0%
Net Margin (TTM)	-257.3%	0.0%
FCF Margin (TTM)	-196.0%	N/A
Net Income (TTM)	$-15M	$-13M
FCF (TTM)	$-12M	$-4M
EPS (TTM)	-$43.57	-$12.94
ROE (TTM)	-25727.0%	0.0%
ROA (TTM)	-15954.0%	-62234.0%
ROIC (TTM)	-23305.0%	0.0%
Financial Health
Cash	$2M	$3M
Debt	$634K	$1M
Net Cash/Debt	$2M	$2M
Current Ratio (TTM)	1.44x	1.12x
Quick Ratio (TTM)	1.36x	0.99x
Debt/Equity (TTM)	0.17x	4.80x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.26	0.75
52W Performance	-89.7%	-95.3%
YTD Performance	-74.2%	-88.3%
% from 52W High	-94.1%	-97.3%
% from 52W Low	3.6%	14.3%
Efficiency & Yields
Asset Turnover (TTM)	0.62x	0.00x
FCF Yield (TTM)	-31.5%	-1.6%
Earnings Yield (TTM)	-41.3%	-5.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-219.2	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BIAF research	View LIMN research